SARMs vs peptides: separating gym lore from actual evidence

What did @coach_mayhem actually say?

The creator laid out what they called a decision tree for performance-enhancing drugs, sorted by goal. "Want size and a bollocks" feeling? Go SARMs. "Feeling and recovery"? Peptides. Lean gains? SARMs again, but cautiously. Fat loss? Fat burners. Focus? Nootropics. And for a "secret weapon," MK-677 and cardarine. The framing is a beginner's guide, packaged as forbidden knowledge nobody will teach you.

This is a PED recommendation video dressed up as education. The creator is not discussing these compounds in a clinical context. There is no mention of prescription requirements, off-label status, physician oversight, or the fact that several of these substances are banned by WADA and have no approved human use. That omission is not a minor footnote. It is the entire regulatory and safety context that a responsible discussion requires.

Does the science back this up?

Partially, in the narrowest sense. The broad categorical split between SARMs and peptides is chemically accurate, but the implied safety profile for each is badly undersold. The specific claims about MK-677 and cardarine are where the science diverges hardest from the hype.

MK-677 (ibutamoren) is a growth hormone secretagogue, not a SARM, and the creator mislabels it by grouping it in the "secret weapon" category alongside cardarine without clarifying either compound's status. Cardarine (GW501516) was abandoned by GlaxoSmithKline after animal studies showed dose-dependent carcinogenesis across multiple tissue types (Oleson and Bhatt, 2013, Toxicological Sciences). Hafner et al. (2014, Cell Metabolism) confirmed the mechanism involves PPAR-delta activation driving tumor cell proliferation. That is not a fringe concern. That is why the drug never made it to Phase III trials. Presenting it as a "secret weapon" without that context is irresponsible.

For peptides broadly, the creator's claim that they support "feeling and recovery" aligns with emerging research on compounds like BPC-157, though most of that data is preclinical (Chang et al., 2011, Journal of Physiology-Paris).

What did they get wrong (or right)?

Right: the general categorical logic that SARMs target androgen receptors and peptides work through different signaling pathways is not wrong. Peptides like BPC-157, TB-500, and CJC-1295 operate through mechanisms distinct from classical androgens. Using peptides as a recovery-focused category is a reasonable, if oversimplified, framing.

Wrong, and significantly: cardarine is not a SARM and not a peptide. It is a PPAR-delta agonist with a discontinued development history specifically because of cancer signals in animal models. Grouping it as a "secret weapon" with MK-677 with zero safety caveat is the kind of claim that gets people hurt. MK-677 does stimulate GH secretion and has shown effects on lean mass in trials (Murphy et al., 1998, Journal of Clinical Endocrinology and Metabolism), but it also raises fasting glucose and has not been approved by the FDA for any indication.

The creator also uses the phrase "less shutdown" for SARMs compared to anabolic steroids. This is a common broscience talking point that is not well supported. SARMs do suppress endogenous testosterone, sometimes severely (Bhasin et al., 2022, Journal of Clinical Endocrinology and Metabolism). "Less" does not mean "safe" or "negligible."

What should you actually know?

SARMs are not approved by the FDA for any human use. The FDA has issued multiple warnings about SARMs being marketed as dietary supplements, citing risks including liver toxicity, cardiovascular effects, and hormonal disruption. Cardarine specifically has not been approved anywhere in the world for human use and was dropped from development due to carcinogenesis findings. MK-677 remains an investigational compound with no approved indication.

Peptides occupy a different regulatory space. Some, like sermorelin, are FDA-approved. Others, like BPC-157, are not approved for human use but are studied in clinical contexts under physician supervision. The distinction between "legal for research" and "approved for human use" matters, and the creator does not draw it.

• Cardarine's carcinogenic signal in animals is not disputed, it is the reason development stopped.
• SARM-induced testosterone suppression can require post-cycle therapy just as conventional AAS does.
• MK-677 raises IGF-1 and GH but also increases fasting glucose, a clinically relevant side effect.
• Peptide therapies with recovery applications exist, but most human evidence is preliminary or anecdotal.
• None of these compounds should be used without physician oversight, regardless of how "mild" they are presented.